Cynapsus Therapeutics Stock Price, News & Analysis (NASDAQ:CYNA)

$40.48 0.01 (0.02 %)
(As of 01/22/2018 01:22 PM ET)
Previous Close$40.47
Today's Range$40.47 - $40.49
52-Week Range$10.54 - $40.67
Volume388,800 shs
Average Volume113,889 shs
Market CapitalizationN/A
P/E Ratio21.76
Dividend YieldN/A
BetaN/A

About Cynapsus Therapeutics (NASDAQ:CYNA)

Cynapsus Therapeutics logoCynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.

Receive CYNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CYNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolNASDAQ:CYNA
CUSIPN/A
Phone+1-416-7032449

Debt

Debt-to-Equity Ratio0.05%
Current Ratio4.45%
Quick Ratio4.44%

Price-To-Earnings

Trailing P/E Ratio21.7634408602151
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$1.86
Net IncomeN/A
Net MarginsN/A
Return on Equity-35.81%
Return on Assets-32.75%

Miscellaneous

Employees25
Outstanding Shares13,150,000

Cynapsus Therapeutics (NASDAQ:CYNA) Frequently Asked Questions

What is Cynapsus Therapeutics' stock symbol?

Cynapsus Therapeutics trades on the NASDAQ under the ticker symbol "CYNA."

How were Cynapsus Therapeutics' earnings last quarter?

Cynapsus Therapeutics Inc (NASDAQ:CYNA) announced its quarterly earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by $0.06. View Cynapsus Therapeutics' Earnings History.

Who are some of Cynapsus Therapeutics' key competitors?

When did Cynapsus Therapeutics IPO?

(CYNA) raised $64 million in an IPO on Thursday, June 18th 2015. The company issued 4,500,000 shares at a price of $14.18 per share. BofA Merrill Lynch acted as the underwriter for the IPO and Nomura and Noble Life Science Partners were co-managers.

How do I buy Cynapsus Therapeutics stock?

Shares of Cynapsus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cynapsus Therapeutics' stock price today?

One share of Cynapsus Therapeutics stock can currently be purchased for approximately $40.48.

How can I contact Cynapsus Therapeutics?

Cynapsus Therapeutics' mailing address is 828 Richmond St W, TORONTO, ON M6J 1C9, Canada. The biotechnology company can be reached via phone at +1-416-7032449.


MarketBeat Community Rating for Cynapsus Therapeutics (CYNA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about Cynapsus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cynapsus Therapeutics (NASDAQ:CYNA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A2.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$40.00
Price Target Upside: N/AN/AN/A117.86% upside

Cynapsus Therapeutics (NASDAQ:CYNA) Consensus Price Target History

Price Target History for Cynapsus Therapeutics (NASDAQ:CYNA)

Cynapsus Therapeutics (NASDAQ:CYNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
8/30/2016Noble FinancialReiterated RatingBuy$50.00N/AView Rating Details
8/16/2016BMO Capital MarketsSet Price TargetBuy$30.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Cynapsus Therapeutics (NASDAQ:CYNA) Earnings History and Estimates Chart

Earnings by Quarter for Cynapsus Therapeutics (NASDAQ:CYNA)

Cynapsus Therapeutics (NASDAQ CYNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2016Q2($0.77)($0.83)ViewN/AView Earnings Details
5/11/2016Q1 2016($0.78)($0.68)ViewN/AView Earnings Details
3/9/2016Q4 2015($0.81)($0.75)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.66)$0.18ViewN/AView Earnings Details
8/14/2015Q2 2015($0.56)($1.22)ViewN/AView Earnings Details
5/8/2015Q1 2015($0.64)ViewN/AView Earnings Details
3/17/2015Q4 2014($0.48)($1.12)ViewN/AView Earnings Details
11/12/2014($0.03)($0.02)ViewN/AView Earnings Details
8/14/2014($0.03)($0.04)ViewN/AView Earnings Details
5/7/2014Q1 2014($0.80)($0.48)ViewN/AView Earnings Details
3/27/2014Q4 2013($0.64)ViewN/AView Earnings Details
11/21/2013Q3 2013($0.48)ViewN/AView Earnings Details
8/22/2013Q2 2013($0.32)($0.48)ViewN/AView Earnings Details
5/23/2013Q1 2013($1.12)ViewN/AView Earnings Details
4/24/2013Q4 2012($0.80)ViewN/AView Earnings Details
8/29/2012Q2 2012($0.32)($0.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cynapsus Therapeutics (NASDAQ:CYNA) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cynapsus Therapeutics (NASDAQ:CYNA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cynapsus Therapeutics (NASDAQ CYNA)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Cynapsus Therapeutics (NASDAQ CYNA) News Headlines

Source:
DateHeadline
Zosano Pharma (ZSAN) vs. Cynapsus Therapeutics (CYNA) Head-To-Head ComparisonZosano Pharma (ZSAN) vs. Cynapsus Therapeutics (CYNA) Head-To-Head Comparison
www.americanbankingnews.com - December 11 at 11:24 PM
Company that attended Noble Financials NobleCon10, 11 & 12 - Cynapsus Therapeutics - acquired by Sunovion PharmaceuticalsCompany that attended Noble Financial's NobleCon10, 11 & 12 - Cynapsus Therapeutics - acquired by Sunovion Pharmaceuticals
finance.yahoo.com - November 7 at 5:07 AM
Cynapsus Therapeutics (CYNA) and Its Peers Critical ReviewCynapsus Therapeutics (CYNA) and Its Peers Critical Review
www.americanbankingnews.com - October 27 at 5:12 AM
Sumitomo Chemical: Riding On The Exciting Self-Driving Automobile Development And The Revival Of Japan Inc.Sumitomo Chemical: Riding On The Exciting Self-Driving Automobile Development And The Revival Of Japan Inc.
seekingalpha.com - June 30 at 5:50 PM
SUNOVION CNS DEVELOPMENT CANADA ULC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal YeSUNOVION CNS DEVELOPMENT CANADA ULC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Ye
biz.yahoo.com - October 25 at 9:24 AM
Sunovion Pharma Completes Acquisition of Cynapsus Therapeutics (CYNA)Sunovion Pharma Completes Acquisition of Cynapsus Therapeutics (CYNA)
www.streetinsider.com - October 22 at 8:48 AM
Sunovion Pharmaceuticals Completes Acquisition of Cynapsus TherapeuticsSunovion Pharmaceuticals Completes Acquisition of Cynapsus Therapeutics
www.businesswire.com - October 22 at 8:48 AM
CYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of AcquisitCYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisit
biz.yahoo.com - October 22 at 8:48 AM
BRIEF-Cynapsus Therapeutics securityholders approve arrangement with Sunovion PharmaceuticalsBRIEF-Cynapsus Therapeutics securityholders approve arrangement with Sunovion Pharmaceuticals
www.reuters.com - October 14 at 4:26 PM
Cynapsus Therapeutics (CYNA) Receives Shareholder Approval for Sunovion Pharma the Plan of ArrangementCynapsus Therapeutics (CYNA) Receives Shareholder Approval for Sunovion Pharma the Plan of Arrangement
www.streetinsider.com - October 14 at 4:26 PM
CYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, FinCYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Fin
biz.yahoo.com - October 13 at 9:45 PM
BRIEF-Sumitomo Dainippon Pharma unit to buy 100 pct stake in Cynapsus Therapeutics Inc. at $624 mlnBRIEF-Sumitomo Dainippon Pharma unit to buy 100 pct stake in Cynapsus Therapeutics Inc. at $624 mln
www.reuters.com - October 5 at 9:44 AM
Cynapsus, Caledonia at 52-Week HighsCynapsus, Caledonia at 52-Week Highs
www.baystreet.ca - September 27 at 4:34 PM
CYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsCYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - September 16 at 4:26 PM
Open Text, Cynapsus Only Stocks at 52-Week HighsOpen Text, Cynapsus Only Stocks at 52-Week Highs
www.baystreet.ca - September 12 at 4:21 PM
CYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Unregistered Sale of Equity SecuritiesCYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
biz.yahoo.com - September 8 at 8:20 AM
Cynapsus Therapeutics (CYNA) Vaulted To A New High After Merger AgreementCynapsus Therapeutics (CYNA) Vaulted To A New High After Merger Agreement
www.rttnews.com - September 3 at 4:15 PM
BRIEF-Sunovion Pharmaceuticals to acquire Cynapsus TherapeuticsBRIEF-Sunovion Pharmaceuticals to acquire Cynapsus Therapeutics
www.reuters.com - September 1 at 9:44 AM
Form 8-K Cynapsus Therapeutics For: Aug 31Form 8-K Cynapsus Therapeutics For: Aug 31
www.streetinsider.com - September 1 at 9:44 AM
Cynapsus Therapeutics (CYNA) Has Leaped To A New High After Bought By SunovionCynapsus Therapeutics (CYNA) Has Leaped To A New High After Bought By Sunovion
www.rttnews.com - September 1 at 9:44 AM
Sunovion Pharmaceuticals to Acquire Cynapsus TherapeuticsSunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
www.businesswire.com - September 1 at 9:44 AM
Cynapsus Receives FDA Fast Track Designation For APL-130277Cynapsus Receives FDA Fast Track Designation For APL-130277
www.rttnews.com - August 29 at 9:15 AM
CYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ECYNAPSUS THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
biz.yahoo.com - August 15 at 4:43 PM
BRIEF-Cynapsus says its positive on its Phase 3 Parkinsons studyBRIEF-Cynapsus says its positive on its Phase 3 Parkinson's study
www.reuters.com - August 15 at 11:48 AM
BRIEF-Ely Gold executes agreement to purchase royalties for gold properties in Nevada, British ColumbiaBRIEF-Ely Gold executes agreement to purchase royalties for gold properties in Nevada, British Columbia
www.reuters.com - August 12 at 4:35 PM

SEC Filings

Cynapsus Therapeutics (NASDAQ:CYNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cynapsus Therapeutics (NASDAQ:CYNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cynapsus Therapeutics (NASDAQ CYNA) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.